Do patients who recovered from COVID-19 possess an immunological memory protecting them against reinfection? If so for how long? Will it vary depending on the population considered e.g. the age of the individual, the treatment received, or the severity of the disease during the first exposure? Addressing these questions is directly relevant to public health policies dealing with confinement /deconfinement decisions as well as for vaccination design and utilization.
A team of scientists at Institut Necker-Enfants Malalades and collaborators at Hôpital Henri Mondor coordinated by Simon Fillatreau, Matthieu Mahévas, Claude-Agnès Reynaud and Jean-Claude Weill have received funding from the French National Research Agency (ANR), which established a scientific task force against COVID-19 at the national level, to examine the immunological memory that remains in affected individuals after the resolution of the infection and is the basis for the protective immunity that determines whether affected individuals can be infected twice.